Table 8 Hypoglycemic and antitumor activities of heteroglycans in REISHI
Heteroglycan^a	Total sugar^b	Uronic acid^c	Protein^d	Sugar composition^e					MW^f	[a]_D	Relative glucose level						Antitumor activity^j
Heteroglycan^a	Total sugar^b	Uronic acid^c	Protein^d	Sugar composition^e					MW^f	[a]_D	Dose	0 h	7 h		24 h^g		Dose, i.p.	Inhibition	Complete regression on day 45
	%	%	%	Fuc	Xyl	Man	Gal	Glu	x 10^-4	(NaOH)	mg/kg i.p.	m^h	m ± SEⁱ	%	m ± SEⁱ	%	mg/kg/days	(%)
Fa-1b	89.8	9.2	0.8	-	6	15	8	100	35	-67.4°	100	100	78±4**	75	88±2**	87	20	20	0/5
FA-2	76.3	14.8	0.9	±	10	11	7	100			100	100	64±2**	62	83±8*	82	50	18	0/5
FA-3	72.4	15.0	0.9	-	12	6	3	100			100	100	63±4**	55	81±3*	78	50	62	2/5
FA-4	78.8	19.1	0.9	2	20	3	8	100			100	100	73±4**	63	104±6	100	40	16	0/5
FA-5	60.7	35.5	0.9	-	50	4	±	100			100	100	73±6**	63	113±5	109	50	10	0/5
FII											100	100	67±4**	55	77±5**	64	100	100	5/5
FII-1	77.0	10.3	6.9	2	1	2	3	100	1~3	-21.1°	100	100	120±4**	99	110±7	91	100	100	5/5
FIII-1											100	100	58±3**	62	72±5**	68	100	85	4/5
FIII-1a	92.0	9.7	6.9	8	13	8	5	100	200	+ 48.8°	100	100	60±4**	65	69±3**	65	100	100	5/5
FIII-1b	95.0	13.0	2.5	4	7	2	±	100	7~10	+ 28.9°	100	100	90±7*	80	106±4	99	100	100	5/5
FIII-2											100	100	80±7**	71	83±6**	78	100	100	5/5
FIII-2a	32.0	5.2	40.6	12	16	14	±	100	200	-96.4°	100	100	86±5**	75	70±5**	67	100	100	5/5
FIII-2b	61.0	7.6	17.5	27	26	18	±	100	4~7	+ 7.6°	100	100	72±2**	63	81±4**	78	100	100	5/5
FIII-3											100	100	59±5**	51	86±3*	83	100	100	5/5
FIII-3a	66.0	9.1	6.2	8	9	11	2	100	3~6	-11.6°	100	100	60±1	60	80±3**	75	100	100	5/5


^a FA: Water-soluble acidic heteroglycan fractions.											^e Molar ratio determined as alditol acetates by GLC.
FII: 3% NH4-oxalate soluble heteroglycan fractions.											^f Measured by a gel filtration method.
FIII: 5% NaOH soluble peptideglycan fractions.											^g Time after administration.
^b Calculated as glucose by the phenol-sulfuric acid method.											^h Plasma glucose level at 0 h: 140 - 170 mg/dl.
^c Calculated as glucuronic acid by a modified carbazol method.											ⁱ Significantly different from control, P < 0.05, *P < 0.01, n = 5.
^d Lowry method or Kjeldahl method (N x 6.25).											^j Sarcoma 180/mice, i.p. method